The AmpliSeq for Illumina sequencing solution offers a highly multiplexed polymerase chain reaction (PCR)-based workflow for use with targets ranging from a few to hundreds of genes in a single run. AmpliSeq for Illumina panels are optimized for clinical cancer research and genetic disease studies.
TruSight Tumor 26 takes a deeper view of variation in solid tumors including lung, colon, melanoma, gastric and ovarian. This enables clinical researchers to identify low-frequency variation across 26 genes for a more comprehensive view of somatic variation.
This panel provides amplicon-based library preparation reagents, DNA QC, sample indexes, and oligos targeting identified regions of interest.
See which solid tumor-related genes are represented in TruSight Tumor 26. View Gene List.
TruSight Tumor 26 is a comprehensive assay for examining relevant cancer genes involved in solid tumors, even in challenging FFPE samples.
| AKT1 | EGFR | GNAS | NRAS | STK11 |
| ALK | ERBB2 | KIT | PDGFRA | TP53 |
| APC | FBXW7 | KRAS | PIK3CA | |
| BRAF | FGFR2 | MAP2k1 | PTEN | |
| CDH1 | FOXL2 | MET | SMAD4 | |
| CTNNB1 | GNAQ | MSH6 | SRC |
A multi-institutional study: Evaluation of a novel technique that uses strand-specific information to increase accuracy in a next-generation sequencing assay to identify somatic DNA variants.
A novel approach that improves detection of somatic DNA variants in solid tumors by next-generation sequencing from FFPE samples.
A novel technique that distinguishes low-level somatic DNA variants from FFPE-induced artifacts in solid tumors by next-generation sequencing (NGS).
Amplicon - DS Somatic Variant Caller
Technical Note | PDF< 1 MB
MiSeq Reporter Amplicon - DS Workflow Reference Guide Documentation
TruSight Tumor 26 Checklist Documentation
TruSight Tumor 26 Consumables and Equipment Documentation
Trusight Tumor 26 Documentation
TruSight Tumor 26 Reference Guide Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
Targeted custom research panels optimized for sequencing specific targets or genomic content of interest.
Comprehensive next-generation sequencing (NGS) assay that targets DNA and RNA variants from the same FFPE sample.
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Targeted panel investigating the exonic regions of 409 genes with known associations to cancer.
Note regarding biomarker patents and other patents unique to specific uses of products: Some genomic variants, including some nucleic acid sequences, and their use in specific applications may be protected by patents. Customers are advised to determine whether they are required to obtain licenses from the party that owns or controls such patents in order to use the product in customer's specific application.
